© 2003 European Society of Cardiology
Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure
a Laboratory for Molecular Cardiology, Medical Clinic II, University of Erlangen-Nuremberg Schwabachanlage 10, Ostfluegel, UG, Erlangen 91054, Germany
b Heart Center Dresden, University of Dresden Dresden, Germany
* Corresponding author. Tel.: +49-91-31-853-5896; fax: +49-91-31-533-165. E-mail address: ch.stumpf{at}web.de
 |
Abstract |
|---|
Background: Inflammation plays a significant contributory role in the pathogenesis of chronic heart failure (CHF). Previous data have shown enhanced plasma levels of proinflammatory cytokines, i.e. TNF-
and IL-6, as well as a persistent immune activation in patients with CHF. Furthermore, the immune modulator CD154 has been receiving increased attention, since it plays a key role in the pathophysiology of multicellular vascular events such as thrombosis, inflammation and atherosclerosis. Since CD154 intitiates and maintains the release of proinflammatory cytokines from endothelial cells, its potential role for the development and progression of CHF is of interest.
Methods: Fifty patients with CHF (aged 66.9±12.6 years, mean ejection fraction 22.1±9.2%, NYHA II–IV, 39 of ischemic origin, 11 with idiopathic dilated cardiomyopathy) and 15 healthy controls (aged 62.5±9.8 years) were examined. Thirty-two patients were taking aspirin (100 mg/day). Blood was drawn from a peripheral vein and immediately fixed with 1% paraformaldehyde, incubated with anti-CD154, anti-P-selectin, and anti-CD61 and thereafter analyzed by flow cytometry.
Results: Patients with CHF showed significantly enhanced expression of platelet-bound CD154 and P-selectin as compared to controls (CD154: median 35.6 25th percentile: 26.3; 75th percentile: 44.6 vs. 12.8; 25th: 6.8; 75th: 15.6 mean fluorescence intensity [MFI], P<0.001; P-selectin: median 3.2 25th percentile: 1.9; 75th percentile: 5.9 vs. 1.4; 25th: 1.2; 75th: 1.9, MFI, P<0.001). CD154 expression on platelets positively correlated with increasing NYHA-class. In contrast, no significant differences in serum levels of soluble CD154 or CD40 expression on monocytes were detected in the study groups. Antiplatelet-therapy with aspirin did not influence CD154 or P-selectin expression on platelets.
Conclusion: Our pilot study demonstrates significantly enhanced levels of CD154 on platelets in patients with CHF. This suggests that the CD40–CD154 axis may contribute to the proinflammatory milieu, which exists in CHF and thus may play a pathogenic role in the development and progression of CHF.
Key Words: Heart failure • Inflammation • Platelets
Received December 31, 2002; Revised March 6, 2003; Accepted June 12, 2003
Supported by grants from the ELAN programme of the medical faculty of the university of Erlangen-Nuremberg, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Schafer, D. Fraccarollo, J. Widder, M. Eigenthaler, G. Ertl, and J. Bauersachs Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer Eur J Heart Fail, April 1, 2009; 11(4): 336 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Waid, G. M. Vaitaitis, N. D. Pennock, and D. H. Wagner Jr Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes J. Leukoc. Biol., August 1, 2008; 84(2): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pignatelli, R. Cangemi, A. Celestini, R. Carnevale, L. Polimeni, A. Martini, D. Ferro, L. Loffredo, and F. Violi Tumour necrosis factor {alpha} upregulates platelet CD40L in patients with heart failure Cardiovasc Res, June 1, 2008; 78(3): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Chung and G. Y.H. Lip Platelets and heart failure Eur. Heart J., November 2, 2006; 27(22): 2623 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater Cardiac Function, Inflammatory Mediators and Mortality in Critical Limb Ischemia Angiology, August 1, 2006; 57(4): 437 - 444. [Abstract] [PDF]
|
|
|
|
|
|
T. Ueland, P. Aukrust, A. Yndestad, K. Otterdal, S. S. Froland, K. Dickstein, J. Kjekshus, L. Gullestad, and J. K. Damas Soluble CD40 ligand in acute and chronic heart failure Eur. Heart J., June 1, 2005; 26(11): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, M. Eigenthaler, P. Tas, A. Firnschild, S. Frantz, G. Ertl, and J. Bauersachs Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of NO Bioavailability Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pignatelli, V. Sanguigni, L. Lenti, D. Ferro, A. Finocchi, P. Rossi, and F. Violi gp91phox-Dependent Expression of Platelet CD40 Ligand Circulation, September 7, 2004; 110(10): 1326 - 1329. [Abstract] [Full Text] [PDF]
|
|